Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of DEFA4 cytokine to preparation of medicaments for treating liver failure

A technology for liver failure and cytokines, applied in the fields of molecular medicine, biomedicine, and clinical medicine, which can solve problems such as shortage of donor livers and death of patients.

Inactive Publication Date: 2019-09-27
ZHEJIANG UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But due to a severe shortage of donor livers, a large number of patients died while waiting for a liver transplant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of DEFA4 cytokine to preparation of medicaments for treating liver failure
  • Application of DEFA4 cytokine to preparation of medicaments for treating liver failure
  • Application of DEFA4 cytokine to preparation of medicaments for treating liver failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Embodiment 1: Injection containing DEFA4 cytokines treats a large animal (young pig) model of liver failure

[0043] Animal model: 30 male Chinese young pigs (8-10 kg) were randomly divided into two groups, 15 in each group. Each young pig was injected with 1.5g / kg of D-gal via the jugular vein to create a liver failure model.

[0044] Test group: multiple intravenous injections of DEFA4 injection at fixed time points after D-gal injection, dose: 10ml / kg, twice a day.

[0045] Control group: inject the same amount of saline without DEFA4.

[0046] Neither the control group nor the experimental group received other drug treatment.

[0047] figure 1 It is a schematic diagram of the survival time curves of the young pigs of the experimental group and the control group, showing the survival rate of the young pigs of the experimental group and the control group. The results showed that the 3-day survival rate of young pigs in the treatment group containing DEFA4 cytokine...

Embodiment 2

[0048] Embodiment 2: The lyophilized powder injection containing DEFA4 cytokine treats the small animal (rat) model of liver failure

[0049] Animal model: 100 male rats (200-250 g) were randomly divided into two groups, 50 in each group. Each rat was intraperitoneally injected with D-gal 1.5g / kg to make a liver failure model. Prepare DEFA4 lyophilized powder and water for injection to form a suspension.

[0050] Experimental group: 4 ml of DEFA4 freeze-dried powder suspension was injected intraperitoneally at a fixed time point after D-gal injection, twice a day.

[0051] Control group: inject the same amount of saline without DEFA4.

[0052] Both the control group and the experimental group received no other drug treatment.

[0053] figure 2 Schematic diagram of the survival time curves of rats in the experimental group and the control group, figure 2The survival rate of the rats in the experimental group and the control group is shown: the results show that the rats ...

Embodiment 3

[0054] Embodiment 3: The suspension containing DEFA4 cytokine treats the rabbit model of hepatic failure

[0055] Animal model: 40 adult male rabbits (2000-2500 g) were randomly divided into two groups, 20 in each group. Each rabbit was intramuscularly injected D-gal 1.5g / kg to make a liver failure model.

[0056] Test group: intramuscular injection of DEFA4 suspension 20ml at fixed time points after D-gal injection, twice a day.

[0057] Control group: inject the same amount of saline without DEFA4.

[0058] Both the control group and the experimental group received no other drug treatment.

[0059] image 3 It is a schematic diagram of the survival time curves of rabbits in the experimental group and the control group, image 3 The survival rate of rabbits in the experimental group and the control group is expressed: the results show that the survival rate of the rabbits in the DEFA4 treatment group is 90% at 1 day, 90% at 7 days, and 90% at 14 days, while the control gr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a DEFA4 cytokine to preparation of medicaments for treating liver failure. The medicaments include pharmaceutically acceptable excipients, antioxidants and carriers of the DEFA4 cytokine. DEFA4 is one of ABCA superfamily members, severe hepatic cell necrosis and apoptosis occur during the liver failure, and bone marrow-derived mesenchymal stem cells play an important role during liver repair. In the application to the preparation of the medicaments for treating the liver failure, the DEFA4 cytokine can significantly improve biochemical indexes of a patient, reduce the bilirubin level, reduce transaminase, improve the blood coagulation function, increase the albumin level, inhibit the hepatic cell death, promote the hepatic cell and bile duct cell regeneration, and prevent occurrence of fatal complications such as upper gastrointestinal bleeding, serious hepatic encephalopathy and hepatorenal syndrome, so that the survival time is significantly prolonged and the survival rate is increased.

Description

technical field [0001] The invention belongs to the fields of clinical medicine, molecular medicine and biomedicine, and is a new technology for treating liver failure with DEFA4 cytokine series drugs, specifically, an application of DEFA4 cytokine in the preparation of medicaments for treating liver failure. Background technique [0002] Liver failure is a kind of disease caused by extensive necrosis of the liver caused by various reasons. Except for orthotopic liver transplantation, there is currently no specific treatment. However, due to the severe shortage of donor livers, a large number of patients died while waiting for liver transplantation. Clarifying the pathogenesis of liver failure and early treatment targeting the mechanism can effectively block the progression of the disease and reduce the mortality rate, which is of great significance to the treatment of liver failure. [0003] The DEFA gene is located on chromosome 8p23.1 and encodes α-defensin. There are c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/19A61P1/16
CPCA61K38/19A61P1/16
Inventor 李君陈新李江梁茜李佳琪江静
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com